HUMA

Humacyte INC

-$16.2M

Net Activity

Institutions Holding

160

Popularity Rank

#3426

Avg Weight

0.02%

Total Value

$36.9M

Ownership Trend

160 institutions currently hold HUMA, with 83 net buyers and 53 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

53

Net Buying Institutions

83

Key Holders

View all 160 holding institutions

Quarterly Activity

Recent Activity

+$24.3M

Total Buy Value

$21.8M

Total Sell Value

New buy29
Trim33
Add54
Sold out20

83

Net Buyers

53

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

1

Active 5%+ Holders

Data as of 2026-07-13
Reporting PersonTypeFiling Date% of Class
Fresenius Medical Care Holdings, Inc.13D/A2026-07-136.8%

View all Schedule 13D/13G filings

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding HUMACYTE INC (HUMA)?
Major stakeholders currently include BlackRock, Inc. ($7.5M), Vanguard Capital Management LLC ($4.3M), ANTIPODES PARTNERS Ltd ($3.5M). Based on the latest 13F filings, there are a total of 160 tracked investment funds and institutions maintaining positions in HUMA.
What is the overall institutional sentiment toward HUMA recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $16.2M, driven by 83 managers accumulating shares while 53 reduced their exposure.
Which institutions have been selling or reducing their HUMA positions?
In the latest period, 33 funds trimmed their holdings, and 20 managers completely exited their positions. The aggregate reported sell value was $21.8M.
Are there any notable investors adding HUMA to their portfolios?
Yes, buying activity remains notable. 29 institutions opened new positions in {ticker}, and 54 existing holders added to their shares. The total reported buy value for the quarter amounted to $24.3M.

Related Stocks